Review: Systemic treatment of advanced colorectal cancer: Tailoring therapy to the tumor

Therapeutic Advances in Gastroenterology

Volumn 1, Issue 1, 2008, Pages 33-42

  Carethers, John M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 fluorouracil; bevacizumab; biologic therapy; cetuximab; chemotherapy; colorectal cancer; epidermal growth factor receptor; tyrosine kinase inhibitor; vascular endothelial growth factor

Indexed keywords

EID: 84993813056     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X08093607     Document Type: Review

References (55)

1. Amado, R.G., Wolf, M., Peeters, M., van Cutsem, E., Siena, S., Freeman, D.J. et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer, J Clin Oncol 26: 1626-34.
2. Arnold, C.N., Goel, A. and Boland, C.R. (2003) Role of hMLH 1 promoter hypermethylation in drug resistance to 5-fluoruracil in colorectal cancer cell lines, Int J Cancer 106: 66-73.
3. Berlin, J., Posey, J., Tchekmedyian, S., Hu, E., Chan, D., Malik, I. et al. (2007) Panitumumab with irinotecan/leucovorin/5-fluoruracil for first-line treatment of metastatic colorectal cacner, Clin Colorectal Cancer 6: 427-432.
4. Best, L., Simmonds, P., Baughan, C., Buchanan, R., Davis, C., Fentiman, I. et al. (2000) Colorectal meta-analysis Collaboration. Palliative chemotherapy for advanced or metastatic colorectal cancer, Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD001545. DOI: 10.1002/14651858.CD001545. Accessed April 8, 2008.
5. Boland, C.R., Sinicrope, F.A., Brenner, D.E. and Care thers, J.M. (2000) Colorectal cancer prevention and treatment, Gastroenterology 118: S115-S128.
6. Care thers, J.M., Chauhan, D.P., Fink, D., Nebel, S., Bresalier, R.S., Howell, S.B. et al. (1999) Mismatch repair proficiency and in vitro response to 5-fluorouracil, Gastroenterology 117: 123-131.
7. Care thers, J.M., Hawn, M.T., Chauhan, D.P., Luce, M.C., Marra, G., Koi, M. et al. (1996) Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine, J Clin Invest 98: 199-206.
8. Care thers, J.M., Smith, E.J., Behling, C.A., Nguyen, L., Tajima, A., Doctolero, R.T. et al. (2004) Use of 5-fluorouracil and survival in patients with microsatellite unstable colorectal cancer, Gastroenterology 126: 394-401.
9. Chung, C.H., Mirakhur, B., Chan, E., Le, Q.T., Berlin, J., Morse, M. et al. (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose, N Engl J Med 358: 1109-1117.
10. Chung, K.Y., Shia, J., Kemeny, N.E., Shah, M., Schwartz, G.K., Tse, A. et al. (2005) Cetuximab shows activity in colorectal cancer patients with turmos that do not express the epidermal growth factor receptor by immunohistochemistry, J Clin Oncol 23: 1803-1810.
11. Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., Chau, I. and van Cutsem, E. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, New Engl J Med 351: 337-45.
12. de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J. et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol 18 (16): 2938-2947.
13. de Vos tot Nedervee Cappel, W.H., Neulenbeld, H.J., Keibeuker, J.H., Nagengast, F.M., Menko, F.H., Griffioen, G. et al. (2004 ) Survival after adjuvant 5-FU treatment for stage III coon cancer in hereditary nonpolyposis colorectal cancer, In J Cancer 109: 468-471.
14. Douillard, J.Y., Cunningham, D., Roth, A.D., Navarro, M., James, R.D., Karasek, P. et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, Lancet 355 (9209): 1041-1047.
15. Ferrara, N., Gerber, H.P. and LeCounter, J. (2003) The biology of VEGF and its receptors, Nat Med 9: 669-676.
16. Gill, S., Loprinzi, C.L., Sargent, D.J., Thomé, S.D., Alberts, S.R., Haller, D.G. et al. (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22: 1797-806.
17. Goldberg, R.M., Sargent, D.J., Morton, R.F., Fuchs, C.S., Ramanathan, R.K., Williamson, S.K. et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol 22 (1): 23-30.
18. Grady, W.M. and Care thers, J.M. (2008) Genomic instability and molecular pathogenesis of colorectal cancer, Gastroenterology (in press).
19. Hardcastle, J.D., Chamberlain, J.O., Robinson, M. H., Moss, S.M., Amar, S.S., Balfour, T.W. et al. (1996) Randomised controlled trial of faecal-occult-blood screening for colorectal cancer, Lancet 348: 1472.
20. Hoskins, J.M., Goldberg, R.M., Qu, P., Ibrahim, J.G. and McLeod, H.L. (2007) UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters, J Natl Cancer Inst 99: 1290-1295.
21. Huang, S., Armstrong, E.A., Benavente, S., Chinnaiyan, P. and Harari, P.M. (2004) Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR); combining anti-EGFR antibody with tyrosine kinase inhibitor, Cancer Res 64: 5355-5362.
22. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med 350 (23): 2335-42.
23. Ingraham, H.A., Tseng, B.Y. and Goulian, M. (1980) Mechanism for exclusion of 5-fluorouracil from DNA, Cancer Res 40: 998-1001.
24. Jemel, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. and Thun, M.J. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
25. Jonker, D.J., O'Callaghan, C.J., Karapetis, C.S., Zalcberg, J.R., Tu, D., Au, H.J. et al. (2007) Cetuximab for the treatment of colorectal cancer, N Engl J Med 357 (20): 2040-2048.
26. Jover, R., Zapater, P., Castells, A., Llor, X., Andreu, M., Cubiella, J. et al. (2006) Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer, Gut 55: 848-855.
27. Klein, C.E., Gupta, E., Reid, J.M., Atherton, P.J., Sloan, J.A., Pitot, H.C. et al. (2002) Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucoronide Clin Pharmacol Ther 72: 638-47.
28. Koopman, M., Antonini, N.F., Douma, J., Wals, J., Honkoop, A.H., Erdkamp, F.L. et al. (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial, Lancet 370: 135-142.
29. Kronborg, O., Fenger, C., Olsen, J., Jørgensen, O.D. and Søndergaard, O. (1996) Randomised study of screening for colorectal cancer with faecal-occult-blood test, Lancet 348: 1467-71.
30. Kuo, T., Cho, C.D., Hasley, J., Wakelee, H.A., Advani, R.H., Ford, J.M. et al. (2005) Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cacner, J Clin Oncol 23: 5613-5619.
31. Laurie, J.A., Moertel, C.G., Fleming, T.R., Wieand, H.S., Leigh, J.E., Rubin, J. et al. (1989) Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil, J Clin Oncology 7: 1447-1456.
32. Lièvre, A., Bachet, J.B., Boige, V., Cayre, A., Le Corre, D., Buc, E. et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab, J Clin Oncol 26: 374-379.
33. Lonn, U. and Lonn, S. (1986) DNA lesions in human neoplastic cells and cytotoxicity of 5-fluoropyrimidines, Cancer Res 46: 3866-3870.
34. Mandel, J.S., Bond, J.H., Church, T.R., Snover, D.C., Bradley, G.M., Schuman, L.M. and Ederer, F. (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 328: 1365-71.
35. Meyers, M., Wagner, M.W., Mazurek, A., Schmutte, C., Fishel, R. and Boothman, D.A. (2005) DNA mismatch repair-dependent response to fluoropyrimidine-generated damage, J Biol Chem 280: 5516-5526.
36. Moertel, C.G., Fleming, T.R., Macdonald, J.S., Haller, D.G., Laurie, J.A., Goodman, P.J. et al. (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma, N Eng J Med 322: 352-358.
37. Moertel, C.G., Fleming, T.R., Macdonald, J.S., Haller, D.G., Laurie, J.A., Tangen, C.M. et al. (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report, Ann Intern Med 122: 321-326.
38. Papouli, E., Cejka, P. and Jiricny, J. (2004) Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells, Cancer Res 64: 3391-3394.
39. Parker, W.B. and Cheng, Y.C. (1990) Metabolism and mechanism of action of 5-fluorouracil, Pharmac Ther 48: 381-395.
40. Parker, W.B., Kennedy, K.A. and Klubes, P. (1987) Dissociation of 5-fluorouracil-induced DNA fragmentation from either its incorporation into DNA or its cytotoxicity in murine T-lymphoma (S-49) cells, Cancer Res 47: 979-982.
41. Petrelli, N., Douglass Jr, H.O., Herrera, L., Russell, D., Stablein, D.M., Bruckner, H.W. et al. (1989) The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group, J Clin Oncol 7 (10): 1419-1426.
42. Ponz-Sarvise, M., Rodriguez, J., Viudez, A., Chopitea, A., Calvo, A., Garcia-Foncillas, J. et al. (2007) Epidermal growth factor receptor inhibitors in colorectal cacner treatment: what's new, World J Gastroenterol 13: 5877-5887.
43. Raymond, E., Faivre, S., Chaney, S., Woynarowski, J. and Cvitkovic, E. (2002) Cellular and molecular pharmacology of oxaliplatin, Mol Cancer Ther 1: 227-235.
44. Ribic, C.M., Sargent, D.J., Moore, M.J., Thibodeau, S.N., French, A.J., Goldberg, R.M. et al. (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer, N Engl J Med 349: 247-257.
45. Rougier, P., van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R. et al. (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cacner, Lancert 352: 1407-1412.
46. Saltz, L.B., Cox, J.V., Blanke, C., Rosen, L.S., Fehrenbacher, L., Moore, M.J. et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group, N Engl J Med 343 (13): 905-914.
47. Seymour, M.T., Maughan, T.S., Ledermann, J.A., Topham, C., James, R., Gwyther, S.J. et al. (2007) FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial, Lancet 370: 143-152.
48. Strumberg, D., Richly, H., Hilger, R.A., Schleucher, N., Korfee, S., Tewes, M. et al. (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors, J Clin Oncol 23: 965-972.
49. Tajima, A., Hess, M.T., Cabrera, B.L., Kolodner, R.D. and Care thers, J.M. (2004) The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance, Gastroenterology 127: 1678-1684.
50. Townsley, C.A., Major, P., Siu, L.L., Dancey, J., Chen, E., Pond, G.R. et al. (2006) Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer, Br J Cancer 94: 1136-1143.
51. van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B. et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compated with best supportive care alon in patients with chemotherapy-refractory metastatic colorectal cacner, J Clin Oncol 25: 1658-1664.
52. Verones, M.L., Sun, W., Giantonio, B., Berlin, J., Shults, J., Davis, L. et al. (2005) A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer, Br J Cancer 92: 1846-1849.
53. Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R.A., Schwartz, B., Simantov, R. and Kelley, S. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer, Nat Rev Drug Discov 5: 835-844.
54. World Health Organization. Available at: http://www.who.int/mediacentre/news/releases/2003/pr27/en/. (accessed April 8, 2008).
55. Yu, C., Bruzek, L.M., Meng, X.W., Gores, G.J., Carter, C.A., Kaufmann, S.H. et al. (2005) The role of Mcl-1 down-regulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006, Oncogene 24: 6861-6869.